Ultragenyx Earnings Call Balances Growth With Risk

Ultragenyx Pharmaceutical, Inc. ((RARE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Ultragenyx Pharmaceutical’s latest earnings call struck a cautiously optimistic tone, pairing solid commercial momentum and advancing late-stage programs with stark reminders of the costs and risks ahead. Management outlined a credible, though execution‑heavy, path to 2027 profitability, while investors must weigh sizable losses, regulatory setbacks and slower growth against a deep rare‑disease pipeline.

Strong Full-Year Revenue Growth

Ultragenyx delivered 2025 revenue of $673 million, up 20% year over year and above the high end of guidance, underscoring durable demand across its rare‑disease portfolio. The upside versus expectations signals that current products can fund a meaningful portion of the pipeline, even as the company remains far from breakeven.

Crysvita Franchise Performance

Flagship drug Crysvita generated $481 million in 2025, a 17% increase versus 2024 and ahead of guidance, with North America contributing $275 million and Latin America and Turkey $177 million. Europe remained modest at $29 million but highlights ongoing geographic expansion for this key cash‑generating asset.

High-Growth Products: Evkeeza and Dojolvi

Evkeeza stood out with $59 million in 2025 revenue, an 84% jump driven largely by demand outside the U.S. and a growing patient base. Dojolvi added $96 million, up 9% year over year, providing steady if slower growth that complements the faster‑ramping assets in the portfolio.

Global Commercial Footprint Expansion

The company now brings treatments to patients in more than 35 countries, illustrating a broadening commercial infrastructure in rare diseases. Evkeeza alone has roughly 350 patients across 20 countries, with reimbursement coverage expanding in key markets that should support further volume gains.

Robust Clinical Follow-up and UX111 Data

For UX111 in MPS IIIA, Ultragenyx now has more than eight years of follow‑up, showing sustained separation on neurologic measures such as Bayley cognition and communication scores. These clinical trends are backed by durable reductions in CSF heparan sulfate biomarkers that appear correlated with disease stabilization or improvement.

Near-Term Regulatory and Clinical Catalysts

Management highlighted two potential approvals in 2026, UX111 for MPS IIIA and DTX401 for GSD Ia, with the rolling BLA for DTX401 complete and a PDUFA action expected in the third quarter of 2026. A pivotal Phase III Aspire readout for GTX‑102 in Angelman syndrome is also slated for the second half of 2026, positioning 2026 as a catalyst‑heavy year.

Restructuring to Drive Path to Profitability

Ultragenyx announced a strategic restructuring aimed at sharpening focus on near‑term value drivers and improving operating leverage, including a 10% workforce reduction of about 130 employees. The company expects combined R&D and SG&A to be flat to down slightly in 2026 versus 2025 and at least 15% lower in 2027 relative to 2025.

Cash and Balance Sheet Actions

At year‑end 2025, the company held $738 million in cash, cash equivalents and marketable securities, a key buffer as it navigates losses and major clinical readouts. Management is also evaluating monetization of two potential Priority Review Vouchers as an additional lever in its plan to bridge to profitability.

Concrete 2026 Revenue Guidance

For 2026, Ultragenyx guided revenue to $730–760 million, implying 8–13% growth over 2025 and excluding any contribution from new launches. Within that, Crysvita is expected to reach $500–520 million and Dojolvi $100–110 million, reinforcing their roles as core revenue pillars while investors wait on pipeline conversions.

Complete Response Letter for UX111 BLA

The bullish UX111 data were tempered by news that the FDA issued a Complete Response Letter for the BLA, asking for additional supportive CMC documentation typically reviewed during inspections. This forces a resubmission and delays the regulatory timeline for MPS IIIA, pushing out a key potential revenue and PRV milestone.

Large Net Loss and High Operating Spend

Despite top‑line growth, Ultragenyx posted a 2025 net loss of $575 million, or $5.83 per share, highlighting the heavy cost of scaling a rare‑disease platform. Combined R&D and SG&A expenses were about $1.1 billion, with cost of sales at $109 million, underscoring the urgency behind the company’s cost‑cutting agenda.

Workforce Reduction and Restructuring Impact

The 10% workforce reduction and cuts across manufacturing, clinical, early‑stage research and G&A are designed to streamline operations around near‑term launches. However, management acknowledged that such changes bring near‑term operational friction and potential morale issues even as they improve the medium‑term financial profile.

Slower Revenue Growth Expected in 2026

Guided 2026 organic growth of 8–13% marks a slowdown versus the 20% achieved in 2025, reflecting maturing franchises and regional variability. In particular, Crysvita should grow but will be partially offset by timing and ordering swings in Brazil and other Latin American markets.

Regulatory Uncertainty on Biomarker Acceptance

The company noted broader FDA scrutiny of biomarker‑driven approaches in ultra‑rare neurologic diseases, a trend seen in recent industry CRLs. This raises risk for programs like UX111 that rely on CSF heparan sulfate and similar biomarkers, potentially complicating approval paths even with strong clinical narratives.

Dependence on Approvals and PRVs for Profitability

Ultragenyx’s route to expected profitability in 2027 leans heavily on securing multiple approvals for UX111, DTX401 and GTX‑102, as well as monetizing PRVs. Any delays, negative data or tougher‑than‑expected regulatory outcomes could materially disrupt that trajectory and prolong cash burn.

Program-Specific Uncertainties: Setrusumab

The Setrusumab ORTHO/Orbit program introduced additional uncertainty after unexpected refractures were seen in the ORBIT cohort, prompting deeper analysis. Management floated hypotheses such as increased activity leading to fractures but emphasized that more work is needed before charting the program’s next steps.

Cash Runway Pressure and Key Assumptions

With $738 million in cash and securities, Ultragenyx believes it has sufficient resources when combined with restructuring savings and potential PRV proceeds. Still, the company modeled PRV monetization only conservatively above $100 million, and uncertainty around timing and pricing keeps some pressure on the runway.

Forward-Looking Guidance and Profitability Path

Looking ahead, management expects 2026 revenue of $730–760 million, with Crysvita at $500–520 million and Dojolvi at $100–110 million, while holding combined R&D and SG&A flat to slightly down versus 2025. For 2027, R&D is projected to fall about 38% from 2025 and combined R&D plus SG&A to decline at least 15%, supporting a plan to reach profitability if clinical and regulatory milestones land on time.

Ultragenyx’s call painted a picture of a company at an inflection point, pairing solid commercial execution and a rich near‑term catalyst slate with notable financial and regulatory strain. For investors, the story hinges on whether upcoming data, approvals and disciplined cost control can convert today’s heavy investment into sustainable profits by 2027.